Experienced in CACH Syndrome

Dr. Sonia Partap

Pediatric Neurology | Pediatrics | Neurology
725 Welch Rd, 
Palo Alto, CA 
Experienced in CACH Syndrome
725 Welch Rd, 
Palo Alto, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Sonia Partap is a Pediatric Neurologist and a Pediatrics provider in Palo Alto, California. Dr. Partap is rated as an Experienced provider by MediFind in the treatment of CACH Syndrome. Her top areas of expertise are Medulloblastoma, Glioma, Embryonal Tumor with Multilayered Rosettes, and Posterior Fossa Tumor.

Her clinical research consists of co-authoring 69 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 2 articles in the study of CACH Syndrome.

Specialties
Pediatric Neurology
Pediatrics
Neurology
Licenses
Pediatrics in CA
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Sutter Health
  • HMO
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Valley Health
  • HMO
View 4 Less Insurance Carriers -

Locations

725 Welch Rd, Palo Alto, CA 94304

Additional Areas of Focus

Dr. Partap has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Neurofibromatosis Type 1 (NF1)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma
A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma
Enrollment Status: Active_not_recruiting
Publish Date: October 06, 2025
Intervention Type: Drug, Other, Radiation
Study Drugs: Cyclophosphamide, Cisplatin, Vincristine, Vismodegib, Pemetrexed, Gemcitabine
Study Phase: Phase 2
A Safety and Preliminary Efficacy Trial of Pembrolizumab (MK-3475) in Children With Recurrent, Progressive or Refractory Diffuse Intrinsic Pontine Glioma (DIPG), Non-Brainstem High-Grade Gliomas (NB-HGG), Ependymoma, Medulloblastoma or Hypermutated Brain Tumors
A Safety and Preliminary Efficacy Trial of Pembrolizumab (MK-3475) in Children With Recurrent, Progressive or Refractory Diffuse Intrinsic Pontine Glioma (DIPG), Non-Brainstem High-Grade Gliomas (NB-HGG), Ependymoma, Medulloblastoma or Hypermutated Brain Tumors
Enrollment Status: Active_not_recruiting
Publish Date: August 01, 2025
Intervention Type: Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 1
Recurrent Medulloblastoma and Primitive Neuroectodermal Tumor Adoptive T Cell Therapy During Recover From Myeloablative Chemotherapy and Hematopoietic Stem Cell Transplantation
Recurrent Medulloblastoma and Primitive Neuroectodermal Tumor Adoptive T Cell Therapy During Recover From Myeloablative Chemotherapy and Hematopoietic Stem Cell Transplantation
Enrollment Status: Completed
Publish Date: April 27, 2025
Intervention Type: Biological
Study Drugs: TTRNA-xALT, TTRNA-DCs
Study Phase: Phase 2
A Phase I Study of Savolitinib in Recurrent, Progressive or Refractory Medulloblastoma, High-Grade Glioma, Diffuse Intrinsic Pontine Glioma, and CNS Tumors Harboring MET Aberrations
A Phase I Study of Savolitinib in Recurrent, Progressive or Refractory Medulloblastoma, High-Grade Glioma, Diffuse Intrinsic Pontine Glioma, and CNS Tumors Harboring MET Aberrations
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2025
Intervention Type: Procedure, Drug
Study Drug: Savolitinib
Study Phase: Phase 1
Phase 2 Study of Alisertib as a Single Agent in Recurrent or Progressive Central Nervous System (CNS) Atypical Teratoid Rhabdoid Tumors (AT/RT) and Extra-CNS Malignant Rhabdoid Tumors (MRT) and in Combination Therapy in Newly Diagnosed AT/RT
Phase 2 Study of Alisertib as a Single Agent in Recurrent or Progressive Central Nervous System (CNS) Atypical Teratoid Rhabdoid Tumors (AT/RT) and Extra-CNS Malignant Rhabdoid Tumors (MRT) and in Combination Therapy in Newly Diagnosed AT/RT
Enrollment Status: Active_not_recruiting
Publish Date: April 10, 2025
Intervention Type: Drug, Radiation, Procedure
Study Drugs: Alisertib, Methotrexate, Cisplatin, Carboplatin, Cyclophosphamide, Etoposide, Topotecan, Vincristine
Study Phase: Phase 2
View 4 Less Clinical Trials

69 Total Publications

A phase 2 PBTC study of selumetinib for recurrent/progressive pediatric low-grade glioma: Strata 2, 5, and 6 with long-term outcomes on strata 1, 3, and 4.
A phase 2 PBTC study of selumetinib for recurrent/progressive pediatric low-grade glioma: Strata 2, 5, and 6 with long-term outcomes on strata 1, 3, and 4.
Journal: Neuro-oncology
Published: April 17, 2025
Similar Doctors
Elite in CACH Syndrome
Dr. Lawrence Steinman
Neurology
Elite in CACH Syndrome
Dr. Lawrence Steinman
Neurology
725 Welch Rd, 
Palo Alto, CA 
 (0.1 miles away)
650-498-5710
Languages Spoken:
English
See accepted insurances

Lawrence Steinman is a Neurologist in Palo Alto, California. Dr. Steinman is rated as a Distinguished provider by MediFind in the treatment of CACH Syndrome. His top areas of expertise are CACH Syndrome, Relapsing Multiple Sclerosis (RMS), Multiple Sclerosis (MS), and Transverse Myelitis.

Distinguished in CACH Syndrome
Dr. Scott S. Zamvil
Neurology
Distinguished in CACH Syndrome
Dr. Scott S. Zamvil
Neurology

Ucsf Medical Group Business Services

1500 Owen St, 
San Francisco, CA 
 (26.0 miles away)
415-476-1000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Scott Zamvil is a Neurologist in San Francisco, California. Dr. Zamvil is rated as a Distinguished provider by MediFind in the treatment of CACH Syndrome. His top areas of expertise are Multiple Sclerosis (MS), CACH Syndrome, Neuromyelitis Optica, and Relapsing Multiple Sclerosis (RMS).

Distinguished in CACH Syndrome
Dr. Jacinda Sampson
Neurology
Distinguished in CACH Syndrome
Dr. Jacinda Sampson
Neurology

Stanford Health Care

300 Pasteur Dr, 
Stanford, CA 
 (0.2 miles away)
650-723-4000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jacinda Sampson is a Neurologist in Stanford, California. Dr. Sampson is rated as an Elite provider by MediFind in the treatment of CACH Syndrome. Her top areas of expertise are Oculodentodigital Dysplasia, Myotonic Dystrophy Type 2, Myotonic Dystrophy, Paramyotonia Congenita, and Thymectomy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Partap's expertise for a condition
ConditionClose
View All 20 Advanced Conditions
View All 159 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile